You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hepatocellular carcinoma (HCC)

Showing 51 - 75 of 9,731
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Dresden, Leipzig, Berlin (Cabozantinib)

Recruiting
  • Hepatocellular Carcinoma
  • Dresden, Saxonia, Germany
  • +2 more
Mar 10, 2022

CT Imaging for Guiding PA-TACE for HCC

Recruiting
  • Carcinoma, Hepatocellular
  • postoperative adjuvant transarterial chemoembolization
  • Guangzhou, Guangdong, China
    ZhuJiang Hospital of Southern Medical University
Nov 30, 2023

Hepatocellular Carcinoma Trial in Guangzhou (SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 9, 2023

Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable Trial in Seoul (Atezolizumab plus

Recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
  • Atezolizumab plus bevacizumab
  • Seoul, Korea, Republic of
    Asan Medical Center
Aug 7, 2023

Advanced Hepatocellular Carcinoma Trial in China (Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Penpulimab injection
  • +2 more
  • Wuwei, Gansu, China
  • +7 more
Jul 27, 2023

Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer Trial in Singapore (Neoantigen Dendritic Cell Vaccine,

Recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Singapore, Singapore
    National Cancer Center Singapore
Aug 17, 2022

Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

Not yet recruiting
  • Melanoma
  • +5 more
  • INCB 99280 with Ipilimumab
  • (no location specified)
Jun 9, 2023

Hepatocellular Carcinoma, HCC Trial in Orange (Nivolumab, Ipilimumab, Cabozantinib)

Recruiting
  • Hepatocellular Carcinoma
  • HCC
  • Orange, California
    Chao Family Comprehensive Cancer Center, University of Californi
Apr 4, 2022

Hepatocellular Carcinoma Trial in Shanghai (M-TACE)

Enrolling by invitation
  • Hepatocellular Carcinoma
  • M-TACE
  • Shanghai, Shanghai, China
    Department of Interventional Radiology, Zhongshan Hospital, Fuda
May 24, 2023

Hepatocellular Carcinoma Trial in United Kingdom (Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Birmingham, United Kingdom
  • +8 more
Apr 12, 2022

Circulatory MicroRNA of Resected Hepatocellular Carcinoma

Recruiting
  • Hepatocellular Carcinoma
    • Singapore, Singapore
    • +5 more
    Aug 15, 2022

    Hepatocellular Carcinoma Trial in Hangzhou (Anlotinib Hydrochloride)

    Terminated
    • Hepatocellular Carcinoma
    • Anlotinib Hydrochloride
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital of Medical School of Zhejiang Univ
    Aug 25, 2022

    Biliary Tract Tumors, Liver Cancer, Hepatocellular Carcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Trans-arterial

    Active, not recruiting
    Has Results
    • Biliary Tract Neoplasms
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Mar 1, 2022

    Cirrhotic Patients With and Without Hepatocellular Carcinoma

    Not yet recruiting
    • Pulmonary Complications of Liver Cirrhosis and HCC
    • spirometry
    • Sohag, Egypt
      Sohag University hospitals
    Jul 26, 2023

    Hepatocellular Carcinoma(HCC), Cirrhotic Portal Hypertension Trial in GuangZhou (Precise hepatectomy, Combined intervention

    Completed
    • Hepatocellular Carcinoma(HCC)
    • Cirrhotic Portal Hypertension
    • Precise hepatectomy
    • Combined intervention (chemoembolization/ablation)
    • GuangZhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 20, 2021

    circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC

    Not yet recruiting
    • Hepatic Cell Carcinoma
      • (no location specified)
      Sep 12, 2023

      Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial (Atezolizumab Injection, Bevacizumab, Transarterial

      Not yet recruiting
      • Hepatocellular Carcinoma
      • BCLC Stage B Hepatocellular Carcinoma
      • Atezolizumab Injection
      • +2 more
      • (no location specified)
      Mar 16, 2023

      Hepatocellular Carcinoma (HCC) Trial in Nancy, Paris (Pexastimogene Devacirepvec (Pexa Vec), Nivolumab)

      Terminated
      Has Results
      • Hepatocellular Carcinoma (HCC)
      • Nancy, France
      • +1 more
      Oct 21, 2021

      Advanced Hepatocellular Carcinoma Trial (HLX07, HLX10, HLX04)

      Not yet recruiting
      • Advanced Hepatocellular Carcinoma
      • (no location specified)
      May 1, 2022

      Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma Trial in Ann Arbor (drug, device, radiation, diagnostic

      Recruiting
      • Hepatocellular Carcinoma (HCC)
      • Unresectable Hepatocellular Carcinoma
      • Ann Arbor, Michigan
        University of Michigan Rogel Cancer Center
      Dec 16, 2021

      Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, sintilimab plus SIRT)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • Lenvatinib, sintilimab plus SIRT
      • Guangzhou, Guangdong, China
        The Second Affiliated Hospital of Guangzhou Medical University
      Aug 8, 2023

      Liver Cancer, Liver Cirrhoses, Liver Carcinoma Trial in La Jolla (Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid)

      Recruiting
      • Liver Cancer
      • +2 more
      • Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
      • La Jolla, California
        University of California, San Diego
      Apr 6, 2022

      Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))

      Recruiting
      • Hepatocellular Carcinoma
      • Lenvatinib Plus Tislelizumab
      • Transarterial Chemoembolization(TACE)
      • Beijing, Beijing, China
        Nan Zhang
      Apr 22, 2023

      Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

      Not yet recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Adjuvant tislelizumab plus lenvatinib
      • Adjuvant tislelizumab
      • Nanning, China
        Jian-Hong Zhong
      Jun 11, 2023

      Hepatocellular Carcinoma Trial in China, United States (CS1003+Lenvatinib, CS1003 Placebo+Lenvatinib)

      Active, not recruiting
      • Hepatocellular Carcinoma
      • Nofazinlimab (CS1003)+Lenvatinib
      • Nofazinlimab (CS1003) Placebo+Lenvatinib
      • Coronado, California
      • +5 more
      Nov 7, 2022